Drug intelligence / Profile preview

VIP217

Development stage: Preclinical
Lead developer: Vincerx
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

VIP217 is a preclinical oncology asset that is part of a bioconjugation platform, which Vincerx Pharma exclusively licensed worldwide from Bayer. This platform is designed to develop next-generation antibody-drug conjugates (ADCs) and small molecule drug conjugates (SMDCs) for cancer therapy. Vincerx Pharma acquired VIP217, along with other assets (VIP236, VIP943, VIP924), to build its pipeline of cancer therapies, leveraging over a decade of Bayer's discovery research. The licensing deal involved an upfront payment and potential future milestone payments and royalties.

Targets

CDK9 (Cyclin-dependent kinase 9)P-TEFb (Positive transcription elongation factor b)

Beyond the preview

Go deeper on VIP217.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIP217.

Explore the full profile